Q3 2025 Nautilus Biotechnology Inc Earnings Call Transcript
Key Points
- Nautilus Biotechnology Inc (NAUT) made significant progress in Q3 2025, advancing their scientific platform and operational priorities towards commercialization.
- The company has established key collaborations with prestigious institutions like the Allen Institute for Brain Science and the Buck Institute for Research on Aging, enhancing their research capabilities.
- Nautilus' iterative mapping method has been recognized for its ability to measure proteoforms with unprecedented resolution, offering a unique advantage over traditional technologies.
- The company has reduced operating expenses by 19% year-over-year, reflecting a focused operating model and improved efficiency.
- Nautilus ended the quarter with a strong cash position of $168.5 million, providing a cash runway extending through 2027.
- Nautilus Biotechnology Inc (NAUT) anticipates only limited revenue in the near term from their early access program, as the focus is on generating high-quality data and validating their platform.
- The company expects operating expenses to increase in future quarters as product and market development activities ramp up.
- Despite progress, the commercial launch of their broadscale assay configuration is not expected until late 2026, indicating a longer timeline before significant revenue generation.
- The company acknowledges that current engagements are unlikely to yield meaningful services revenue in 2026.
- Nautilus is still in the process of building their sales and commercial team, which may delay their ability to capitalize on market opportunities.
Good day and thank you for standing by. Welcome to the Nautilus Biotechnology third-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today, Ji-Yon Yi, Investor Relations. Please go ahead.
Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30, 2025. If you haven't received this news release or if you'd like to be added to the company's distribution list, please send an e-mail to [email protected].
Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; Ken Suzuki, Chief Marketing Officer; and Anna Mowry, Chief Financial Officer.
Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
